MeiraGTx : MGTX

MGTX

Stock Data

$7.42

$0.27 (3.51%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

MeiraGTx Holdings plc is a pioneering force in the field of gene therapy, dedicated to crafting innovative treatments for serious diseases. With a focus on ocular diseases such as inherited retinal diseases and degenerative conditions, as well as neurodegenerative diseases and xerostomia, the company is advancing a diverse portfolio of therapies. Its research spans from early to mid-stage clinical trials, including efforts to combat achromatopsia, X-linked retinitis pigmentosa, and Parkinson’s disease. Founded in 2015 and headquartered in New York, MeiraGTx collaborates with Janssen Pharmaceuticals to push the boundaries of gene therapy for inherited retinal diseases.